Effects of Sugammadex versus Neostigmine on Intraoperative Coagulation Profiles in Patients with Thyroidectomy

Background Sugammadex has been a revolutionary reversal of neuromuscular blockade. It is known to be highly efficient. However, a change in the coagulation profile is one of the most dangerous potential complications which is a concern for both surgeon and anesthetist. Bleeding may cause hypovolemic shock, hematoma, and so on. To investigate the effects of sugammadex on coagulation profiles in patients with thyroidectomy, we compared patients that were treated with either sugammadex or neostigmine. Patients and Methods Eighty patients with thyroid neoplasms undergoing thyroidectomy were randomly allocated to sugammadex group (group S) or neostigmine group (group N). Induction of anesthesia was preformed using propofol, sufentanil, and rocuronium. Group S received sugammadex 2.0mg/kg after trachea intubation, similarly Group N received neostigmine 40 µg/kg, for reversal of rocuronium-induced neuromuscular blockade. The intraoperative coagulation profiles were monitored after the rocuronium injection (T0), 10 minutes after reversal (T1) and 30 minutes after reversal (T2) by testing activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (FIB), thrombin time (TT), and TEG-Haemonetics. Amount of bleeding was recorded during perioperative period. Results There was no significant difference in the thromboelastogram, APTT, PT, FIB, or TT measurements at each time point in Group N. The reaction time (R time) and kinetics time (K time) of Group S in T1 were significantly longer than the corresponding times at T0 and T2, and the R times were significantly longer than those in Group N at the same time points (P<0.05). Additionally, in Group S, the APTT was prolonged in T1 and returned to normal in T2. Conclusion The result showed that sugammadex provided transient efficacy in prolonging the coagulation parameters, while neostigmine did not change the coagulation profile.

[1]  Na Young Kim,et al.  Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study. , 2019, Journal of clinical anesthesia.

[2]  B. Donahue,et al.  Retrospective Analysis of the Safety and Efficacy of Sugammadex Versus Neostigmine for the Reversal of Neuromuscular Blockade in Children. , 2019, Anesthesia and analgesia.

[3]  T. Fuchs-Buder,et al.  Deep neuromuscular blockade improves surgical conditions during gastric bypass surgery for morbid obesity: A randomised controlled trial. , 2019, European journal of anaesthesiology.

[4]  W. Schreiner,et al.  Combined recurrent laryngeal nerve monitoring and one-lung ventilation using the EZ-Blocker and an electromyographic endotracheal tube , 2019, Journal of Cardiothoracic Surgery.

[5]  G. Udeani,et al.  EVALUATION OF SUGAMMADEX VS NEOSTIGMINE IN THE REVERSAL OF NEUROMUSCULAR BLOCKADE , 2018, Chest.

[6]  M. Eikermann,et al.  Therapeutic doses of neostigmine, depolarising neuromuscular blockade and muscle weakness in awake volunteers: a double‐blind, placebo‐controlled, randomised volunteer study , 2018, Anaesthesia.

[7]  Young Sung Kim,et al.  In vitro investigation of the effects of exogenous sugammadex on coagulation in orthopedic surgical patients , 2018, BMC Anesthesiology.

[8]  R. Borna,et al.  Sugammadex: Clinical Pharmacokinetics and Pharmacodynamics , 2018, Current Anesthesiology Reports.

[9]  A. Abad-Gurumeta Evidence of residual neuromuscular block with sugammadex vs neostigmine. , 2018, British journal of anaesthesia.

[10]  P. Simioni,et al.  Effect of sugammadex on coagulation as detected by rotational thromboelastometry in morbidly obese patients. , 2018, Minerva anestesiologica.

[11]  E. Erdas,et al.  Intraoperative neuromonitoring in thyroid surgery: Is the two-staged thyroidectomy justified? , 2017, International journal of surgery.

[12]  Chun-Liang Chen,et al.  Application of transoral continuous intraoperative neuromonitoring in natural orifice transluminal endoscopic surgery for thyroid disease: a preliminary study , 2017, Surgical Endoscopy.

[13]  S. Visser,et al.  A PK-PD model-based assessment of sugammadex effects on coagulation parameters. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  I. Kissin,et al.  A quest to increase safety of anesthetics by advancements in anesthesia monitoring: scientometric analysis , 2015, Drug design, development and therapy.

[15]  P. Jorens,et al.  Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: A randomised controlled study in healthy volunteers , 2015, European journal of anaesthesiology.

[16]  C. Kluft,et al.  Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. , 2014, International journal of clinical pharmacology and therapeutics.

[17]  R. Redfern,et al.  Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent , 2008, Drug design, development and therapy.